477 related articles for article (PubMed ID: 17254483)
1. Inhibition of rho kinase attenuates high flow induced pulmonary hypertension in rats.
Li FH; Xia W; Li AW; Zhao CF; Sun RP
Chin Med J (Engl); 2007 Jan; 120(1):22-9. PubMed ID: 17254483
[TBL] [Abstract][Full Text] [Related]
2. Long-term inhibition of Rho kinase with fasudil attenuates high flow induced pulmonary artery remodeling in rats.
Li F; Xia W; Li A; Zhao C; Sun R
Pharmacol Res; 2007 Jan; 55(1):64-71. PubMed ID: 17127075
[TBL] [Abstract][Full Text] [Related]
3. [Expression and activity of RhoA/Rho kinase in remodeling of high blood flow pulmonary vessels.].
Li FH; Xia W; Sun RP
Zhonghua Er Ke Za Zhi; 2007 May; 45(5):387-92. PubMed ID: 17697629
[TBL] [Abstract][Full Text] [Related]
4. Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats.
Abe K; Shimokawa H; Morikawa K; Uwatoku T; Oi K; Matsumoto Y; Hattori T; Nakashima Y; Kaibuchi K; Sueishi K; Takeshit A
Circ Res; 2004 Feb; 94(3):385-93. PubMed ID: 14670839
[TBL] [Abstract][Full Text] [Related]
5. Involvement of RhoA/Rho kinase signaling in pulmonary hypertension of the fawn-hooded rat.
Nagaoka T; Gebb SA; Karoor V; Homma N; Morris KG; McMurtry IF; Oka M
J Appl Physiol (1985); 2006 Mar; 100(3):996-1002. PubMed ID: 16322374
[TBL] [Abstract][Full Text] [Related]
6. Acute vasodilator effect of fasudil, a Rho-kinase inhibitor, in monocrotaline-induced pulmonary hypertension in rats.
Jiang BH; Tawara S; Abe K; Takaki A; Fukumoto Y; Shimokawa H
J Cardiovasc Pharmacol; 2007 Feb; 49(2):85-9. PubMed ID: 17312448
[TBL] [Abstract][Full Text] [Related]
7. Fasudil hydrochloride hydrate, a Rho-kinase inhibitor, suppresses 5-hydroxytryptamine-induced pulmonary artery smooth muscle cell proliferation via JNK and ERK1/2 pathway.
Chen XY; Dun JN; Miao QF; Zhang YJ
Pharmacology; 2009; 83(2):67-79. PubMed ID: 19052484
[TBL] [Abstract][Full Text] [Related]
8. Attenuation of pulmonary hypertension secondary to left ventricular dysfunction in the rat by Rho-kinase inhibitor fasudil.
Dai ZK; Wu BN; Chen IC; Chai CY; Wu JR; Chou SH; Yeh JL; Chen IJ; Tan MS
Pediatr Pulmonol; 2011 Jan; 46(1):45-59. PubMed ID: 20717937
[TBL] [Abstract][Full Text] [Related]
9. Long-term inhibition of Rho-kinase ameliorates hypoxia-induced pulmonary hypertension in mice.
Abe K; Tawara S; Oi K; Hizume T; Uwatoku T; Fukumoto Y; Kaibuchi K; Shimokawa H
J Cardiovasc Pharmacol; 2006 Dec; 48(6):280-5. PubMed ID: 17204906
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of RhoA/Rho kinase pathway is involved in the beneficial effect of sildenafil on pulmonary hypertension.
Guilluy C; Sauzeau V; Rolli-Derkinderen M; Guérin P; Sagan C; Pacaud P; Loirand G
Br J Pharmacol; 2005 Dec; 146(7):1010-8. PubMed ID: 16205723
[TBL] [Abstract][Full Text] [Related]
11. Rho-kinase inhibition alleviates pulmonary hypertension in transgenic mice expressing a dominant-negative type II bone morphogenetic protein receptor gene.
Yasuda T; Tada Y; Tanabe N; Tatsumi K; West J
Am J Physiol Lung Cell Mol Physiol; 2011 Nov; 301(5):L667-74. PubMed ID: 21856816
[TBL] [Abstract][Full Text] [Related]
12. Endothelial nitric oxide synthase-enhancing G-protein coupled receptor antagonist inhibits pulmonary artery hypertension by endothelin-1-dependent and endothelin-1-independent pathways in a monocrotaline model.
Liu CP; Dai ZK; Huang CH; Yeh JL; Wu BN; Wu JR; Chen IJ
Kaohsiung J Med Sci; 2014 Jun; 30(6):267-78. PubMed ID: 24835346
[TBL] [Abstract][Full Text] [Related]
13. Rho-kinase as a potential therapeutic target for the treatment of pulmonary hypertension.
Xing XQ; Gan Y; Wu SJ; Chen P; Zhou R; Xiang XD
Drug News Perspect; 2006 Nov; 19(9):517-22. PubMed ID: 17220956
[TBL] [Abstract][Full Text] [Related]
14. Rho kinase-mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats.
Oka M; Homma N; Taraseviciene-Stewart L; Morris KG; Kraskauskas D; Burns N; Voelkel NF; McMurtry IF
Circ Res; 2007 Mar; 100(6):923-9. PubMed ID: 17332430
[TBL] [Abstract][Full Text] [Related]
15. Rescue treatment with a Rho-kinase inhibitor normalizes right ventricular function and reverses remodeling in juvenile rats with chronic pulmonary hypertension.
Xu EZ; Kantores C; Ivanovska J; Engelberts D; Kavanagh BP; McNamara PJ; Jankov RP
Am J Physiol Heart Circ Physiol; 2010 Dec; 299(6):H1854-64. PubMed ID: 20889845
[TBL] [Abstract][Full Text] [Related]
16. ROCK controls matrix synthesis in vascular smooth muscle cells: coupling vasoconstriction to vascular remodeling.
Chapados R; Abe K; Ihida-Stansbury K; McKean D; Gates AT; Kern M; Merklinger S; Elliott J; Plant A; Shimokawa H; Jones PL
Circ Res; 2006 Oct; 99(8):837-44. PubMed ID: 16990566
[TBL] [Abstract][Full Text] [Related]
17. Recent progress in the treatment of pulmonary arterial hypertension: expectation for rho-kinase inhibitors.
Fukumoto Y; Tawara S; Shimokawa H
Tohoku J Exp Med; 2007 Apr; 211(4):309-20. PubMed ID: 17409670
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of phosphatidylinositol 3-kinase/Akt signaling attenuates hypoxia-induced pulmonary artery remodeling and suppresses CREB depletion in arterial smooth muscle cells.
Garat CV; Crossno JT; Sullivan TM; Reusch JE; Klemm DJ
J Cardiovasc Pharmacol; 2013 Dec; 62(6):539-48. PubMed ID: 24084215
[TBL] [Abstract][Full Text] [Related]
19. [Fasudil reverses monocrotaline-induced pulmonary hypertension in rats].
Jiang H; Guan RJ; Wang HY
Zhonghua Xin Xue Guan Bing Za Zhi; 2013 Mar; 41(3):239-44. PubMed ID: 23879951
[TBL] [Abstract][Full Text] [Related]
20. Dexfenfluramine discontinuous treatment does not worsen hypoxia-induced pulmonary vascular remodeling but activates RhoA/ROCK pathway: consequences on pulmonary hypertension.
Desbuards N; Antier D; Rochefort GY; Apfeldorfer CS; Schenck E; Hanton G; Hyvelin JM
Eur J Pharmacol; 2009 Jan; 602(2-3):355-63. PubMed ID: 19049806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
